Lecanemab, marketed as Leqembi, is the first drug for Alzheimer’s disease to receive approval on the basis of clinically slowing the progression of Alzheimer’s disease.
Attending a high school with a high number of teachers with graduate training was the clearest predictor of the impact of school quality on late-life cognition, researchers found.
Columbia Nursing researchers are using AI analysis of voice recordings to find a quick, inexpensive way to screen home care patients for early dementia.
Columbia neurologists are investigating a set of blood tests that, used in combination with memory tests, may help physicians correctly diagnose Alzheimer disease in low-resource environments.
Indira Turney, an associate research scientist in the Department of Neurology, is studying how lived experiences affect they way the brain ages in diverse populations.
In a nationally representative study of cognitive impairment prevalence, Columbia researchers found almost 10% of older adults have dementia and 22% have mild cognitive impairment.
Research from Scott Small's lab at Columbia University suggests a different approach to tackling the disease, and a new startup company is now trying to turn that approach into treatments.
A gene called FMNL2 may explain why people with hypertension, diabetes, heart disease, or obesity have a greater risk of developing Alzheimer's disease.
A new Columbia study suggests that malfunctioning endosomes—a central trafficking station inside neurons—are commonly involved in the appearance of Alzheimer’s disease.
Ancient parts of the brain may hold secrets that help explain the drive to eat and how eating may affect brain health. Sabrina Diano, the new Institute of Human Nutrition director, is investigating.
A new study of Alzheimer’s genes suggests the disease in Blacks and whites is largely the same, but genetic changes that increase the risk of developing the disease differ between the two groups.